| Project/Area Number |
26350516
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
Yanase Noriko 東京医科大学, 医学部, 講師 (10210303)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
水口 純一郎 東京医科大学, その他部局等, 名誉教授 (20150188)
秦 喜久美 東京医科大学, 医学部, 講師 (30287156)
豊田 博子 東京医科大学, 医学部, 助手 (80468660)
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | ガンワクチン / ナノ粒子 / 樹状細胞 / ナノテクノロジー / がんワクチン / CTL |
|---|
| Outline of Final Research Achievements |
NPs are composed for hydrophilic and hydrophobic polymers without side effects. To examine the antitumor effect of NPs, we prepared the NPs (NPs-TRP2 / CpG / anti-DEC 205) containing a tumor associated antigen peptide (TRP-2) and an adjuvant (CpG) with an anti-DCs Ab(anti-DEC 205) to its surface. The melanoma cell line B16-F10 was inoculated s.c. in mice, and the NPs was injected on days 5 and 12. The tumor growth was confirmed with the tumor size on the 15th day, it was 459 mm 3 in the control group , but was strongly suppressed at 42 mm 3 in the NPs injected group. Furthermore, number of CD11c + CD86 + cells increased compared to the control group in lymphnode of the NPs-treated mice, thus activated DCs were enhanced. From the above, it was shown that the NPs designed at this is useful as a cancer vaccine.
|
